Absynth Biologics discovers and develops vaccines and antibodies to prevent and treat bacterial infections; based on a platform for identifying novel protein antigen targets that harness the immune system and that use a dual-action mechanism:
- Direct antibacterial activity by antibody-mediated inhibitory effect; and
- Engagement of classic immune effector functions to eliminate the bacteria
Founded by Fusion IP (now part of IP Group plc; www.ipgroupplc.com) Absynth has established a vaccine pipeline targeting the pathogens Staphylococcus aureus, Clostridium difficile and Streptococcus pyogenes. There are no marketed vaccines for any of these pathogens and a limited number of candidates in clinic trials. Consequently, each of Absynth’s pipeline programmes addresses an unmet market need with peak sales estimated to be >$1 billion p.a.
Bacterial infections remain a major cause of death, with microbial drug resistance being a significant contributing factor. Antibiotic resistance now is a global problem, which world health leaders have described as “. a catastrophic threat” to people worldwide. It is now broadly accepted that a multi-pronged approach is needed to address the impact of antibiotic resistance including new antibiotics, vaccines and antibodies, alongside improved practices to control disease transmission.